GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Capex-to-Operating-Income

Recce Pharmaceuticals (ASX:RCE) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Recce Pharmaceuticals's Capital Expenditure for the six months ended in Dec. 2024 was A$-0.02 Mil. Its Operating Income for the six months ended in Dec. 2024 was A$-14.02 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Recce Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Recce Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Capex-to-Operating-Income Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - - -

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Recce Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Recce Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recce Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Capex-to-Operating-Income falls into.


;
;

Recce Pharmaceuticals Capex-to-Operating-Income Calculation

Recce Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.142) / -22.051
=N/A

Recce Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.018) / -14.021
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recce Pharmaceuticals  (ASX:RCE) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Recce Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Recce Pharmaceuticals Business Description

Traded in Other Exchanges
Address
180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

Recce Pharmaceuticals Headlines

No Headlines